Key Takeaways
- AstraZeneca’s breast cancer treatment camizestrant received a 6-3 vote against approval from FDA’s ODAC panel
- Prostate cancer therapy Truqap earned strong 7-1 endorsement from a separate advisory committee
- Shares traded 1.13% lower in premarket sessions at $185.25
- Analysts at Morgan Stanley highlighted potential regulatory challenges stemming from the camizestrant decision
- Company maintains conviction in camizestrant’s clinical trial outcomes despite advisory setback
AstraZeneca encountered diverging outcomes from FDA advisory committees on Thursday, receiving endorsement for one oncology treatment while facing rejection for another.
Shares declined 1.13% during premarket hours Friday, trading at $185.25. Throughout the preceding month, AZN decreased approximately 6.9%, contrasting with the S&P 500’s 9.9% gain during the identical timeframe.
The FDA’s Oncologic Drugs Advisory Committee conducted evaluations of two separate AstraZeneca cancer therapies during a single session, delivering starkly contrasting recommendations.
Regarding camizestrant, the committee delivered a 6-3 vote against the oral breast cancer medication designed for first-line treatment of HR-positive, HER2-negative advanced breast cancer in patients with ESR1 mutations.
Panel members concluded that camizestrant failed to demonstrate substantial clinical benefit for patients whose condition had yet to advance beyond initial therapy.
The SERENA-6 study revealed that camizestrant achieved a 56% decrease in disease advancement or mortality. Trial participants receiving the medication experienced a median progression-free period of 16 months, exceeding the 9.2-month median observed with existing standard treatments.
Committee members expressed reservations regarding the completeness of crucial secondary endpoints, particularly overall survival metrics and time to second disease progression, during the interim review phase.
Subsequent pre-specified analysis demonstrated statistically significant PFS2 advantages, showing 25.7 months compared to 19.1 months, while overall survival data continued displaying favorable trends for camizestrant.
AstraZeneca expressed disappointment regarding the advisory outcome while reaffirming confidence in the clinical evidence and therapeutic value for patients.
Wall Street Analysts Highlight Regulatory Uncertainty
Morgan Stanley research team, headed by Sarita Kapila, characterized the outcome as introducing regulatory uncertainty and potentially dampening market confidence.
Analysts acknowledged that FDA approval remains within the realm of possibility, though the 6-3 committee vote diminishes probability for the SERENA-6 indication. The agency maintains independence from advisory panel recommendations, though historically tends to align with committee guidance. Final regulatory determination awaits.
Prostate Cancer Treatment Earns Strong Advisory Support
AstraZeneca secured positive news regarding Truqap (capivasertib), as ODAC delivered a 7-1 endorsement for the therapy when combined with abiraterone and androgen deprivation therapy in PTEN-deficient metastatic hormone-sensitive prostate cancer patients.
The favorable recommendation stemmed from Phase 3 CAPItello-281 trial findings, demonstrating a 19% reduction in disease progression or mortality risk.
Patients receiving the Truqap combination achieved median radiographic progression-free survival of 33.2 months, surpassing the control group’s 25.7-month median.
Additional study endpoints similarly supported the combination approach, including extended time to castration resistance development and enhanced PSA marker responses.
The safety assessment aligned with established profiles for these treatment modalities, although Grade 3 or higher adverse reactions occurred more frequently among Truqap recipients. Overall survival information continues developing while showing favorable directional trends for the combination regimen.
AZN shares have remained relatively unchanged year-to-date, while the S&P 500 has advanced 4.8% during the corresponding period.
